Tiagabine and exacerbation of essential tremor

Authors

  • Theresa A. Zesiewicz MD, FAAN,

    1. Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Parkinson's Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    2. Department of Molecular Therapeutics, James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA
    3. Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Parkinson's Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Kelly L. Sullivan MSPH,

    1. Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Parkinson's Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    2. Department of Molecular Therapeutics, James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA
    3. Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Parkinson's Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Christopher L. Ward LMT,

    1. Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Parkinson's Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    2. Department of Molecular Therapeutics, James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA
    3. Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Parkinson's Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Robert A. Hauser MD, FAAN

    1. Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Parkinson's Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    2. Department of Molecular Therapeutics, James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA
    3. Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Parkinson's Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author

No abstract is available for this article.

Ancillary